Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/205331
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Valero Martínez, Cristina | - |
dc.contributor.author | Font Urgelles, Judit | - |
dc.contributor.author | Sallés, Meritxell | - |
dc.contributor.author | Joven Ibáñez, Beatriz E. | - |
dc.contributor.author | Juanes, Alexia de | - |
dc.contributor.author | Ramírez, Julio | - |
dc.contributor.author | Juanola, Xavier | - |
dc.contributor.author | Almodóvar, Raquel | - |
dc.contributor.author | Laiz, Ana | - |
dc.contributor.author | Moreno, Mireia | - |
dc.contributor.author | Pujol, Manel | - |
dc.contributor.author | Beltrán, Emma | - |
dc.contributor.author | Pinto Tasende, José Antonio | - |
dc.contributor.author | Crespí, Laura | - |
dc.contributor.author | Sala Icardo, Luis | - |
dc.contributor.author | Castañeda, Santos | - |
dc.contributor.author | García Vicuña, Rosario | - |
dc.date.accessioned | 2024-01-08T13:56:24Z | - |
dc.date.available | 2024-01-08T13:56:24Z | - |
dc.date.issued | 2023-10-23 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | http://hdl.handle.net/2445/205331 | - |
dc.description.abstract | Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. This is a retrospective, real-world multicenter study in refractory SpA and PsA patients with simultaneous use of two biological or synthetic targeted agents. Effectiveness was assessed using Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Disease Activity in Psoriatic Arthritis (DAPSA) Score. We identified 39 different DTT combinations in 36 patients (22 SpA; 14 PsA), 25 of them with concomitant inflammatory bowel disease. The most commonly used combinations were TNF inhibitor plus antagonist of the IL12/23 pathway, followed by TNF inhibitor plus IL-17 antagonist. During a median exposure of 14.86 months (IQR 8-20.2), DTT retention rate was 69.4% (n=25/36; 19 SpA, 6 PsA). Major clinical improvement (change in ASDAS-CRP > 2 or improvement > 85% in DAPSA) was achieved in 69.4% of patients (n=25/36 therapeutical combinations; 17/21 SpA, 8/15 PsA), with a 58.3% (n=21/36 combinations; 15/20 SpA, 6/13 PsA) low-activity/remission rate. Of the patients who were receiving glucocorticoids, 55% managed to withdraw them during follow-up. Interestingly, only four serious adverse events in three patients were observed, leading to DTT discontinuation. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2023.1283251 | - |
dc.relation.ispartof | Frontiers in Immunology, 2023, vol. 14 | - |
dc.relation.uri | https://doi.org/10.3389/fimmu.2023.1283251 | - |
dc.rights | cc by (c) Valero Martínez, Cristina et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Malalties de les articulacions | - |
dc.subject.classification | Malalties inflamatòries intestinals | - |
dc.subject.other | Joints diseases | - |
dc.subject.other | Inflammatory bowel diseases | - |
dc.title | Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2024-01-08T12:41:12Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37936691 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-14-1283251.pdf | 1.29 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License